Q2 FY2026 EarningsYARW.US Q2 FY26 results slightly beat consensus on earnings while underperforming on operating cash flow. Net loss was $3.01M (EPS -$3.51), narrowing compared to the prior year as the company wound down legacy R&D activities in anticipation of its merger with Yarrow. Revenue remains negligible at $0.097M, derived solely from legacy royalties. Post-quarter merger completion and concurrent $200M financing have significantly altered the capital structure, providing a cash runway into 2028.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Yarrow Bioscience(YARW) the EBIT is -6.696 M (--%), Miss estimate;the EPS is -2.14 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B--
-0.01B--
-0.00B--%
EPSMiss expectations
-2.14--
-0.22--
-1.9200--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf